Find information on thousands of medical conditions and prescription drugs.

Viadur

Leuprolide is a gonadotropin-releasing hormone agonist (GnRH agonist). By causing constant stimulation of the pituitary GnRH receptors, it intially causes stimulation (flare), but thereafter decreases pituitary secretion (downregulation) of gonadotropins luteinizing hormone (LH) and follicle stimulating hormone (FSH). Like other GnRH agonists, leuprolide may be used in the treatment of hormone-responsive cancers such as prostate cancer or breast cancer, estrogen-dependent conditions (such as endometriosis or uterine fibroids), to treat precocious puberty, and to control ovarian stimulation in IVF. more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
Hydrocodone
Vagifem
Valaciclovir
Valcyte
Valganciclovir
Valine
Valium
Valnoctamide
Valproate semisodium
Valproic acid
Valpromide
Valrelease
Valsartan
Valstar
Valtrex
Vancenase
Vanceril
Vancomycin
Vaniqa
Vanticon
Vecuronium bromide
Velcade
Velivet
Venlafaxine
Ventolin
Vepesid
Verapamil
Verelan
Vermox
Versed
Vfend
Viadur
Viagra
Vicoprofen
Vidarabine
Vidaza
Videx
Vigabatrin
Viloxazine
Vinblastine
Vincristine
Vinorelbine
Viomycin
Vioxx
Viracept
Viread
Visine
Vistide
Visudyne
Vitaped
Vitrase
Vivelle
Volmax
Voltaren
Voriconazole
Vosol
W
X
Y
Z

Leuprolide acetate is marketed by Bayer AG under the brand name Viadur, by Sanofi-Aventis under the brand name Eligard, and by TAP Pharmaceuticals under the brand name Lupron.

Read more at Wikipedia.org


[List your site here Free!]



Bayer Submits Vardenafil Nda For Erectile Function
Bayer Corporation has submitted a New Drug Application (NDA) for vardenafil, an investigational compound for the improvement of erectile function, to ...
Alza Corp. to acquire Crescendo Pharmaceuticals for 41.67 times revenue, The
The Deal: The Alza Corp has announced that it has exercised its option to purchase the Crescendo Pharmaceuticals Corp. for $100 million in cash. Crescendo, ...
Priority Healthcare Announces Second Quarter Results - Record Quarterly Sales
LAKE MARY, Fla, July 29 /PRNewswire-FirstCall/ -- Priority Healthcare Corporation reported results for the second quarter ended July 2, 2005. For ...
MethylGene Announces Appointment of Dr. Robert E. Martell as Vice President and Chief Medical Officer
MONTREAL -- MethylGene Inc. (TSX:MYG), a biopharmaceutical company, today announced the appointment of Robert E. Martell, M.D., Ph.D., as Vice President ...
Research and Markets: Basic Platform Report: Prostate Cancer
DUBLIN, Ireland -- Prostate Cancer Therapeutics Analysed: a Solid Presentation of the Exciting and Rapidly Evolving Area Research and Markets (http://www.researchandmarkets.com) ...
Research and Markets: Business Development and R&D Database: Prostate Cancer
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com) has announced the addition of Business Development and R&D Database: ...
Bayer Submits New Drug Application — NDA — for Vardenafil for Improvement of Erectile Function; Bayer Files NDA for its Lead Pipeline Product
Business/Health Editors WEST HAVEN, Conn.--(BW HealthWire)--Sept. 25, 2001 Today, Bayer Corporation submitted the New Drug Application (NDA) for ...
Vardenafil Study Shows Positive Results in Erectile Function for Men With Diabetes
Health & Medical Editors/Writers PHILADELPHIA--(BW HealthWire)--June 25, 2001 First Phase III Data Show 72 Percent Response Rate in Men With Diabetes, ...

Home Contact Resources Exchange Links ebay